Nuvation Bio Announces FDA Partial Clinical Hold For Phase 1 Study Of NUV-422 In Solid Tumors
Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug